Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

RAPT Therapeutics (RAPT) Income towards Parent Company: 2018-2023

Historic Income towards Parent Company for Therapeutics (RAPT) over the last 6 years, with Dec 2023 value amounting to -$127.1 million.

  • Therapeutics' Income towards Parent Company fell 35.96% to -$33.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$127.1 million, marking a year-over-year decrease of 48.10%. This contributed to the annual value of -$127.1 million for FY2023, which is 48.10% down from last year.
  • Therapeutics' Income towards Parent Company amounted to -$127.1 million in FY2023, which was down 48.10% from -$85.8 million recorded in FY2022.
  • In the past 5 years, Therapeutics' Income towards Parent Company registered a high of -$43.0 million during FY2019, and its lowest value of -$127.1 million during FY2023.
  • Moreover, its 3-year median value for Income towards Parent Company was -$85.8 million (2022), whereas its average is -$94.0 million.
  • Data for Therapeutics' Income towards Parent Company shows a maximum YoY tumbled of 48.10% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Therapeutics' Income towards Parent Company stood at -$43.0 million in 2019, then dropped by 23.01% to -$52.9 million in 2020, then plummeted by 30.84% to -$69.2 million in 2021, then dropped by 23.97% to -$85.8 million in 2022, then crashed by 48.10% to -$127.1 million in 2023.